A Retrospective Analysis of the Clinical and Epidemiological Characteristics of COVID-19 Patients in Henan Provincial People’s Hospital, Zhengzhou, China

Jing Zhao 1†, Hao-Yu Gao 2†, Zi-Yi Feng 2 and Qi-Jun Wu 3*  
1 Department of Laboratory, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China, 2 Department of Student, China Medical University, Shenyang, China, 3 Department of Clinical Epidemiology, Clinical Research Center, Shengjing Hospital of China Medical University, Shenyang, China

Objective: This study evaluated the clinical and epidemiological characteristics of patients with confirmed coronavirus disease 2019 (COVID-19).

Methods: This retrospective study evaluated 29 patients with confirmed COVID-19 infection admitted to Henan Provincial People’s Hospital between January 27 and February 27, 2020, with follow-up until April 01, 2020.

Results: The median age of the patients was 56 years. Nineteen (19/29; 65.5%) had underlying conditions including cardiovascular disease, digestive disease, or type 2 diabetes mellitus. Twenty-two (22/29; 76%) had close contact with acquaintances or family members who were confirmed or probable COVID-19 cases. Many patients had white blood cell counts with abnormal neutrophil and lymphocyte numbers, abnormal hemoglobin concentration, coagulation profiles, and blood biochemistry, and increased infection markers. Mottling and multiple ground-glass opacities were seen in X-ray images of 19 patients (19/29; 65.5%). Most patients (23/29; 79.8%) received supplemental oxygen therapy and antibiotics (23/29; 79.8%) in addition to traditional Chinese medicines (26/29; 89.7%). The most frequent presenting symptoms were fever, cough, and sputum production. One patient, an 86-years-old woman with more than one underlying disease, died during follow-up. Patients with severe disease were significantly older and more likely to have been transferred from other healthcare facilities than those with mild disease. Anemia, decreased activated partial thromboplastin time, calcium, and albumin, and increased D-dimer and interleukin-6 were more frequent in severe disease. Need of oxygen therapy, mechanical ventilation, intravascular immunoglobulin, and duration of antibiotic therapy were increased in those with severe disease.

Conclusions: Significant differences in demographical and clinical characteristics were observed in patients with moderate and severe COVID-19.

Keywords: coronavirus disease 2019, SARS-CoV-2, epidemiology, clinical characteristics, traditional Chinese medicine
INTRODUCTION

Human infections caused by a novel SARS-CoV-2 corona virus first appeared in Wuhan, China, in December 2019, and by early 2020 the outbreak of coronavirus disease 2019 (COVID-19) had progressed to a global pandemic. The initial cases of COVID-19 were described as a pneumonia of unknown etiology. The first four patients were exposed in the Huanan (Southern China) Seafood Market (1). Initially, the pneumonia presented with symptoms of respiratory infection, but some patients experienced severe disease that ultimately progressed to acute respiratory distress syndrome (ARDS), or even death. COVID-19 has had a great impact on Wuhan, other regions of China, and most other countries worldwide. As of April 01, 2020, there have been 82,631 confirmed infections in all 34 Chinese Provincial Administrative Regions that caused 3,321 deaths. The latest World Health Organization (WHO) Situation Report includes 823,626 infections and 40,598 deaths in more than 200 countries, territories, and areas (2). The pandemic is a serious threat to health worldwide. The basic reproduction number of SRAS-CoV-2 was estimated to be between 2.24 and 3.58 (3, 4).

Coronaviruses that are closely related to SARS-CoV can be found in bats, and there is strong evidence that SARS-CoV came from Chinese horseshoe bats (5). Similarly, MERS-CoV was transmitted by mainly dromedary camels, but it has been found in more than 14 bat species and may also have originated from bats (6). Evolutionary analysis indicates that bats are the most likely host of SARS-CoV-2 and that the virus was transmitted to humans by some unknown intermediate host that was sold at the Hunan Seafood Market (7). Both SARS-CoV-2 and SARS-CoV share angiotensin-converting enzyme 2 (ACE2) as a functional receptor, which mediates binding to host cells and disease transmission (8–10). Located in the north of Hubei province, Henan is one of the six provincial administrative regions bordering Hubei, and one of several most populated provinces and important integrated transportation hubs in China. The region is connected to Hubei in many ways on a considerable level (11). Huge population numbers frequently flow between the two provinces, especially from/to Wuhan, as the provincial capital and where original infections were reported. SARS-CoV-2 infections were reported in Henan shortly after the beginning of the outbreak in Hubei and has the third largest number of confirmed cases on a provincial level, with more than 1,200 infections and 22 deaths (12). Although the COVID-19 outbreak is spreading rapidly, information about infections imported to provinces outside of Hubei is limited. This study describes the epidemiological, laboratory, and clinical features of 29 confirmed COVID-19 patients admitted to Henan Provincial People's Hospital, Zhengzhou, which was one of three hospitals in Henan designated to admit patients with severe COVID-19 infections.

MATERIALS AND METHODS

Patients and Study Design

The emergence of COVID-19 cases in Henan province alerted local health authorities, and the Henan provincial government prohibited travel and began admitting all patients with severe infections to Henan Provincial People's Hospital beginning on January 17, 2020 (13). Despite strict preventive and control measures, such as banning provincial public transportation and rules on wearing protective face masks in public, imported cases continued to emerge in Henan. The first 29 patients who were diagnosed with severe COVID-19 following the WHO interim guidelines (14) and admitted for treatment were included in this study. The admission dates were Jan 27 to Feb 27, 2020, and the cutoff for data collection was April 01, 2020.

Data Collection

The clinical characteristics, laboratory findings, treatment regimens, chest X-rays, and computed tomography (CT) images were retrieved from electronic medical records. The records were verified by the Henan Provincial Center for Disease Control and Prevention to avoid possible bias. Epidemiological information including recent contacts and travel, time of illness onset, first admission, hospital transfer, and discharges were retrieved from medical records or interviews with attending physicians. Patients were transferred to Henan Provincial People's Hospital from other parts of Henan because of the severity of their infection, or were admitted locally in Zhengzhou. SARS-CoV-2 infection was confirmed by a positive reverse-transcription polymerase chain reaction (RT-PCR) assay. Data collection was carried out independently by two investigators and reviewed by two different investigators.

Laboratory Confirmation and Treatment

Patient sputum for assays of viral, bacterial, or fungal infections was collected on admission. The initial evaluation included general status, age and gender, laboratory tests including complete blood count, coagulation assays, serum biochemistry (including alanine aminotransferase, aspartate aminotransferase, creatinine, total bilirubin, blood urea nitrogen, creatine kinase, lactate dehydrogenase, myoglobin, and glucose), and electrolytes. Symptoms, signs, travel, and contact history within the 14 days before onset, hospital transfer information (if any), chronic diseases, and treatment and clinical outcomes were also collected. Following the diagnosis and treatment guidelines (fifth edition) of the Chinese National Health Commission (15), patients were discharged after two independent negative RT-PCR assays with an interval of at least 24 h.

COVID-19 severity was graded following the diagnostic criteria of the National Health Commission of the People's Republic of China (fifth edition) (15). Mild cases were asymptomatic or presented with few symptoms; imaging found no evidence of pneumonia. Moderate cases presented with fever, symptoms of respiratory tract infection, and signs of pneumonia on imaging. Severe cases presented with any of the following: respiratory rate ≥30 breaths/min, peripheral oxygen saturation (SpO₂) ≤93%, or oxygen partial pressure/fractional inspired oxygen (PaO₂/FIO₂) ≤300 mmHg (1 mmHg = 1.33 kPa). Critical cases presented with any of the following: respiratory failure with need of mechanical ventilation, shock, or other organ failure that required ICU admission.
### TABLE 1 | Baseline clinical and demographic characteristics of the COVID-19 patients.

| Characteristics                                      | All patients | Moderate | Severe | P-value |
|-------------------------------------------------------|--------------|----------|--------|---------|
| Number of cases                                       | 29           | 8        | 21     | <0.05   |
| Age at diagnosis, median (IQR)                        | 56.0 (31.5–66.0) | 31.0 (25.8–53.3) | 59.0 (48.5–75.0) | 0.11    |
| Gender, no. (%)                                       |              |          |        |         |
| Male                                                  | 14 (48.3)    | 2 (25)   | 13 (61.9) |         |
| Female                                                | 15 (51.7)    | 6 (75)   | 8 (38.1)  |         |
| Underlying diseases, no. (%)                          |              |          |        | 0.39    |
| Yes                                                   | 19 (65.5)    | 4 (50)   | 15 (71.4) |         |
| No                                                    | 10 (34.5)    | 4 (50)   | 6 (28.6)  |         |
| Underlying disease types, no. (%)                     |              |          |        | N/A     |
| Cardiovascular disease                                | 10 (34.5)    | 1 (12.5) | 9 (42.9)  |         |
| Type 2 diabetes mellitus                              | 7 (24.1)     | 0        | 7 (33.3)  |         |
| Respiratory system disease                            | 4 (13.8)     | 0        | 4 (19)    |         |
| Digestive system disease                              | 8 (27.6)     | 3 (37.5) | 5 (23.8)  |         |
| Parkinson’s disease                                   | 1 (3.4)      | 0        | 1 (4.8)   |         |
| Autoimmune disease                                    | 1 (3.4)      | 0        | 1 (4.8)   |         |
| More than one disease                                 | 8 (27.6)     | 0        | 8 (38.1)  |         |
| A history of traveling to Wuhan or Hubei, no. (%)     |              |          |        | 0.68    |
| Yes                                                   | 9 (31)       | 3 (37.5) | 6 (28.6)  |         |
| No                                                    | 20 (69)      | 5 (62.5) | 15 (71.4) |         |
| Close contact with a confirmed or probable case of nCoV infection, no. (%) |          |        |        | 1.00    |
| Yes                                                   | 22 (75.9)    | 6 (75)   | 16 (76.2) |         |
| No                                                    | 7 (24.1)     | 2 (25)   | 5 (23.8)  |         |
| Presence in a healthcare facility where nCoV infections have been managed, no. (%) |          |        |        | 0.55    |
| Yes                                                   | 4 (13.8)     | 0        | 4 (19)    |         |
| No                                                    | 25 (86.2)    | 8 (100)  | 17 (81)   |         |
| Transferred patients, no. (%)                         |              |          |        | <0.05   |
| Yes                                                   | 20 (69)      | 2 (25)   | 18 (85.7) |         |
| No                                                    | 9 (31)       | 6 (75)   | 3 (14.3)  |         |
| Days from illness onset to first admission, median (IQR) | 3.0 (0.5–6.0) | N/A      | 3.0 (0.5–6.0) | N/A     |

COVID-19, coronavirus disease; IQR, interquartile range; nCoV, novel coronavirus; N/A, not available. P-values are from Mann–Whitney U-tests, chi-square, or Fisher’s exact tests that compared the moderate- and severe-disease groups.

### Statistical Analysis

Statistical analysis was performed with SPSS 26.0 (IBM Corp., Armonk, NY, USA). The values of continuous variables were reported as medians and interquartile range (IQR). Categorical variables were reported as numbers and percentages. The Mann–Whitney U-test was used to compare differences in continuous variables. Values of categorical variables were compared by chi-square or Fisher’s exact tests. All P-values were two-sided and those that were <0.05 were considered significant.

### Ethical Approval

The study was approved by the Ethics Commission of the Henan Provincial People’s Hospital (No. 20200090) and was conducted following the ethical principles of the World Medical Association Declaration of Helsinki.

### RESULTS

#### Patient Characteristics and Epidemiological Data

The baseline clinical and demographic characteristics are shown in Table 1. The median age at diagnosis was 56 (IQR, 31.5–66.0). Nineteen (19/29; 65.5%) had underlining diseases. The most frequent were cardiovascular disease (10/29; 34%), digestive system disease (8/29; 27.5%), and type 2 diabetes mellitus (7/29; 24%). Eight patients (8/29; 27.5%) had more than one underlying disease. Nine (9/29; 31%) had traveled to Wuhan or Hubei. Twenty-two (22/29; 76%) patients had close contact with acquaintances or family members who were confirmed or probable COVID-19 cases, and the majority had been transferred from another hospital. When stratified by disease severity, patients with severe disease tended to be significantly older and were more likely to have been transferred from another healthcare facility (P < 0.05).

#### Laboratory, CT, and X-Ray Evaluation

The laboratory and imaging results are shown in Table 2. Fifteen patients (15/29; 52%) had lymphopenia, six (6/29; 21%) had leukopenia, and six had leukocytosis. Sixteen (16/29; 55%) had low hemoglobin and seven (7/29; 24%) had low platelet counts. Coagulation abnormalities included increased D-dimer in 14 patients (14/29; 48%) and low prothrombin and activated partial thromboplastin time in 13 patients (13/29; 45%). Assays of infection markers found that C-reactive protein was increased in 23 patients (23/29; 79%), serum ferritin was increased in 16 (16/29; 55%), procalcitonin was increased in six (6/29;
| Characteristics                      | All patients (n = 29) | Severity | P-value |
|--------------------------------------|-----------------------|----------|---------|
|                                      |                       | Moderate (n = 8) | Severe (n = 21) |
| **LABORATORY TEST**                  |                       |           |         |
| White blood cell count (×10/L; normal range 3.5–9.5) | 0.15 |
| Increased                            | 6 (20.7)              | 0         | 6 (28.6) |
| Normal                               | 17 (58.6)             | 5 (62.5)  | 12 (57.1) |
| Decreased                            | 6 (20.7)              | 3 (37.5)  | 3 (14.3)  |
| Neutrophils (×10/L; normal range 1.8–6.3) | 0.09 |
| Increased                            | 6 (20.7)              | 0         | 6 (28.6) |
| Normal                               | 18 (65.1)             | 5 (62.5)  | 13 (61.9) |
| Decreased                            | 5 (17.2)              | 3 (37.5)  | 2 (9.5)   |
| Lymphocytes (×10/L; normal range 1.1–3.2) | 0.43 |
| Normal                               | 14 (48.3)             | 5 (62.5)  | 9 (42.9)  |
| Decreased                            | 15 (51.7)             | 3 (37.5)  | 12 (57.1) |
| Platelets (×10/L; normal range 125.0–350.0) | 0.66 |
| Increased                            | 3 (10.3)              | 1 (12.5)  | 2 (9.5)   |
| Normal                               | 19 (65.5)             | 6 (75)    | 13 (61.9) |
| Decreased                            | 7 (24.1)              | 1 (12.5)  | 6 (28.6)  |
| Hemoglobin (g/L; normal range 130.0–175.0) | <0.05 |
| Increased                            | 0                     | 0         | 0        |
| Normal                               | 13 (44.8)             | 7 (87.5)  | 6 (28.6)  |
| Decreased                            | 16 (55.2)             | 1 (12.5)  | 15 (71.4) |
| **COAGULATION PROFILE, NO. (%)**     |                       |           |         |
| Activated partial thromboplastin time (s; normal range 28.0–43.5) | <0.05 |
| Increased                            | 2 (6.9)               | 0         | 2 (9.5)   |
| Normal                               | 14 (48.3)             | 8 (100)   | 6 (28.6)  |
| Decreased                            | 13 (44.8)             | 0         | 13 (61.9) |
| Prothrombin time (s; normal range 11.0–17.0) | 0.80 |
| Increased                            | 1 (3.4)               | 0         | 1 (4.8)   |
| Normal                               | 15 (51.7)             | 4 (50)    | 11 (52.4) |
| Decreased                            | 13 (44.8)             | 4 (50)    | 9 (42.9)  |
| D-dimer (µg/L; normal range 0.0–0.5) | <0.05 |
| Increased                            | 14 (48.3)             | 1 (12.5)  | 13 (61.9) |
| Normal                               | 15 (51.7)             | 7 (87.5)  | 8 (38.1)  |
| **SERUM ELECTROLYTE CONCENTRATION, NO. (%)** |           |           |         |
| Potassium (mmol/L; normal range 3.5–5.5) | 0.64 |
| Increased                            | 1 (3.4)               | 0         | 1 (4.8)   |
| Normal                               | 26 (89.7)             | 7 (87.5)  | 19 (90.5) |
| Decreased                            | 2 (6.9)               | 1 (12.5)  | 1 (4.8)   |
| Sodium (mmol/L; normal range 135.0–145.0) | 0.44 |
| Increased                            | 3 (10.3)              | 0         | 3 (14.3)  |
| Normal                               | 21 (72.4)             | 7 (87.5)  | 14 (66.7) |
| Decreased                            | 5 (17.2)              | 1 (12.5)  | 4 (19)    |
| Calcium (mmol/L; normal range 2.2–2.6) | <0.05 |
| Increased                            | 0                     | 0         | 0        |
| Normal                               | 5 (17.2)              | 4 (50)    | 1 (4.8)   |
| Decreased                            | 24 (82.8)             | 4 (50)    | 20 (95.2) |
| Chloride (mmol/L; normal range 95–105) | 0.24 |
| Increased                            | 13 (44.8)             | 2 (25)    | 11 (52.4) |
| Normal                               | 16 (55.2)             | 6 (75)    | 10 (47.6) |

(Continued)
| Characteristics | All patients (n = 29) | Severity | P-value |
|-----------------|----------------------|----------|---------|
|                 |                      | Moderate (n = 8) | Severe (n = 21) |
| **BLOOD BIOCHEMISTRY, NO. (%)** | | | |
| Alanine aminotransferase (U/L; normal range 9.0–50.0) | | | 0.32 |
| Increased | 3 (10.3) | 0 | 3 (14.3) |
| Normal | 24 (82.8) | 8 (100) | 16 (76.2) |
| Decreased | 2 (6.9) | 0 | 2 (9.5) |
| Aspartate aminotransferase (U/L; normal range 15.0–40.0) | | | 0.17 |
| Increased | 6 (20.7) | 0 | 6 (28.6) |
| Normal | 22 (75.9) | 8 (100) | 14 (66.7) |
| Decreased | 1 (3.4) | 0 | 1 (4.8) |
| Albumin (g/L; normal range 40.0–55.0) | | <0.05 |
| Increased | 6 (20.7) | 4 (50) | 2 (9.5) |
| Normal | 23 (79.3) | 4 (50) | 19 (90.5) |
| Decreased | 2 (6.9) | 0 | 2 (9.5) |
| Total bilirubin (µmol/L; normal range 5.0–21.0) | | 0.65 |
| Increased | 2 (6.9) | 0 | 2 (9.5) |
| Normal | 23 (79.3) | 7 (87.5) | 16 (76.2) |
| Decreased | 4 (13.8) | 1 (12.5) | 3 (14.3) |
| Blood urea (mmol/L; normal range 2.5–7.1) | | 0.12 |
| Increased | 6 (20.7) | 0 | 6 (28.6) |
| Normal | 21 (72.4) | 8 (100) | 13 (61.9) |
| Decreased | 2 (6.9) | 0 | 2 (9.5) |
| Serum creatinine (µmol/L; normal range 44.0–104.0) | | 0.30 |
| Increased | 1 (3.4) | 0 | 1 (4.8) |
| Normal | 19 (65.5) | 7 (87.5) | 12 (57.1) |
| Decreased | 9 (31) | 1 (12.5) | 8 (38.1) |
| Creatine kinase (U/L; normal range 50.0–310.0) | | 0.80 |
| Increased | 1 (3.5) | 0 | 1 (4.7) |
| Normal | 13 (44.8) | 4 (50) | 9 (42.9) |
| Decreased | 15 (51.7) | 4 (50) | 11 (52.4) |
| Lactate dehydrogenase (U/L; normal range 120.0–250.0) | | 0.24 |
| Increased | 13 (44.8) | 2 (25) | 11 (52.4) |
| Normal | 16 (55.2) | 6 (75) | 10 (47.6) |
| Myoglobin (ng/mL; normal range 23.0–112.0) | | 0.24 |
| Increased | 5 (17.3) | 0 | 5 (23.8) |
| Normal | 19 (65.5) | 7 (87.5) | 12 (57.2) |
| Decreased | 5 (17.2) | 1 (12.5) | 4 (19) |
| Glucose (mmol/L; normal range 3.9–6.1) | | 0.10 |
| Increased | 12 (41.4) | 1 (12.5) | 11 (52.3) |
| Normal | 16 (55.2) | 7 (87.5) | 9 (42.9) |
| Decreased | 1 (3.4) | 0 | 1 (4.8) |
| **BIOLOGICAL INDICATORS OF INFECTION, NO. (%)** | | | |
| Procalcitonin (ng/mL; normal range 0–0.25) | | | 0.15 |
| Increased | 6 (20.7) | 0 | 6 (28.6) |
| Normal | 23 (79.3) | 8 (100) | 15 (71.4) |
| Interleukin-6 (pg/mL; normal range 1.18–5.3) | | <0.05 |
| Increased | 16 (55.2) | 1 (12.5) | 15 (71.4) |
| Normal | 13 (44.8) | 7 (87.5) | 6 (28.6) |
| Erythrocyte sedimentation rate (mm/h; normal range 0.0–40.0) | | 0.14 |
| Increased | 7 (24.1) | 0 | 7 (33.3) |
| Normal | 22 (75.9) | 8 (100) | 14 (66.7) |

(Continued)
TABLE 2 | Continued

| Characteristics | All patients \( (n = 29) \) | Severity | \( P \)-value |
|-----------------|-----------------------------|----------|--------------|
|                 | Moderate \( (n = 8) \) | Severe \( (n = 21) \) |               |
| Serum ferritin (ng/mL; normal range 21.8–274.1) | | | |
| Increased       | 16 (55.2) | 4 (50) | 12 (57.1) | 0.26 |
| Normal          | 12 (41.4) | 3 (37.5) | 9 (42.9) |
| Decreased       | 1 (3.4) | 1 (12.5) | 0 |
| C-reactive protein (mg/L; normal range 0.0–10.0) | | | 1.00 |
| Increased       | 23 (79.3) | 6 (75) | 17 (81) |
| Normal          | 6 (20.7) | 2 (25) | 4 (19) |
| Decreased       | 0 | 0 | 0 |
| Co-infection, no. (%) | | | | 0.14 |
| Yes             | 7 (24.1) | 0 | 7 (33.3) |
| No              | 22 (75.9) | 8 (100) | 14 (66.7) |
| Co-infection type, no. (%) | | | N/A |
| Bacteria        | 7 (24.1) | 0 | 7 (33.3) |
| Fungus          | 4 (13.8) | 0 | 4 (19) |
| Both            | 4 (13.8) | 0 | 4 (19) |
| CT and chest x-ray imaging, no. (%) | | | N/A |
| Unilateral pneumonia | 5 (17.2) | 1 (12.5) | 4 (19) |
| Bilateral pneumonia | 6 (20.7) | 0 | 6 (28.6) |
| Multiple mottling and ground-glass opacity | 19 (65.5) | 6 (75) | 13 (61.9) |

COVID-19, coronavirus disease 2019; CT, computed tomography; N/A, not available.

\( P \)-values: chi-square or Fisher’s exact tests to compare the moderate- and severe-disease groups.

21%), and the erythrocyte sedimentation rate was increased in seven (7/29; 24%). A few patients had electrolyte disorders, but 24 (24/29; 83%) had decreased calcium levels. Bacterial and fungal cultures were done if infections were suspected. Seven patients (7/29; 24%) were diagnosed with bacterial coinfections, including six lung and one urinary system infection. Four (4/29; 13.8%) had fungal infections. Chest CT and/or X-ray imaging showed bilateral pneumonia in 23 patients (23/29; 79%) with multiple mottling and ground-glass opacity in 19 (19/29; 65.5%). Five (5/29; 17%) had unilateral pneumonia. When stratified by severity, we found that patients with severe infections were more likely to have anemia, decreased activated partial thromboplastin time, calcium, and albumin, and increased D-dimer and interleukin-6 (\( P < 0.05 \)).

**Outcomes**

Symptoms on admission and clinical outcomes of the COVID-19 patients are shown in Table 4. The three most common symptoms in patients with mild and severe disease on admission were fever, cough, and sputum production. Fever, cough, and fatigue were the three most common symptoms in patients with moderate disease. By March 10, 2020, 28 patients had been discharged and one had died. The patient who died was an 86-years-old woman who had been transferred to Henan Provincial People’s Hospital. On admission, she had a lumbar spine tumor (benign or malignant unknown), hypertension, coagulopathy, multiple bone fractures caused by trauma 2 months previously, a 10-years history of untreated coronary heart disease, and sequelae of a cerebral infarction 4 years previously. When she was transferred, severe pneumonia had already developed. She was immediately admitted to the ICU, intubated for mechanical ventilation, and given antibiotics and antiviral treatment plus TCM. On the second day, 12 h of continuous renal replacement therapy was performed because of worsening renal damage. The patient soon developed a right atrial thrombus, deep vein thrombosis, and right heart failure. Finally, she died on March 11.

**Treatment Characteristics**

Six of the 29 patients (6/29; 21%), were admitted to the ICU, all of whom had severe infections (Table 3). The majority of those patients (23/29; 80%) received oxygen therapy, antibiotics including cephalosporins, quinolones, and beta lactams, and 26 (26/29; 90%) received traditional Chinese medicines (TCMs), including Qing Fei Pai Du Tang, She Gan Ma Huang Tang, and Xiao Chai Hu Tang, which are recommended for pneumonia prevention and control by the China National Health Commission (15). Herbals, such as nutmeg, bitter almonds, licorice, Chen Pi (dried mandarin peel), ginger, honeysuckle, forsythia, pinellia, trichosanthes, and others were included in the prescriptions. The patients who received TCMs were discharged after 11.9 ± 7.0 days. Three patients without TCM treatment were discharged after 12.3 ± 3.2 days. The trend toward a shorter hospital stay with TCM is consistent with a previous report (16). When stratified by severity, patients with severe disease were more likely to need oxygen therapy, mechanical ventilation, intravenous immunoglobulin therapy, and an increased duration of antibiotic therapy (\( P < 0.05 \)). Two patients with severe disease were treated with extracorporeal membrane oxygenation.
### TABLE 3 | Treatment of the COVID-19 patients.

|                          | All patients (n = 29) | Severity | P-value |
|--------------------------|-----------------------|----------|---------|
|                          | Moderate (n = 8)       | Severe (n = 21) |         |
| **Intensive care unit admission, n (%)** |                       |           |         |
| Yes                      | 6 (20.7)              | 0        | 6 (28.6) | 0.14    |
| No                       | 23 (79.3)             | 8 (100)  | 15 (71.4) |
| **Oxygen therapy, n (%)** |                       |           | <0.05   |
| Yes                      | 24 (82.8)             | 4 (50)   | 20 (95.2) |
| No                       | 5 (17.2)              | 4 (50)   | 1 (4.8)  |
| **Mechanical ventilation, n (%)** |                   |           | <0.05   |
| Non-invasive             | 19 (65.5)             | 4 (50)   | 15 (71.4) |
| Invasive                 | 5 (17.2)              | 0        | 5 (23.8)  |
| No                       | 5 (17.2)              | 4 (50)   | 1 (4.8)  |
| **Antibiotics, n (%)**   |                       |           | 0.65    |
| Yes                      | 23 (79.3)             | 7 (87.5) | 16 (76.2) |
| No                       | 6 (20.7)              | 1 (12.5) | 5 (23.8)  |
| **Duration, median days (IQR)** |                   |           | <0.05   |
|                          | 7.0 (4.0–12.0)        | 3.0 (3.0–8.0) | 8.5 (4.5–14.3) |
| **Antifungal therapy, n (%)** |                   |           | 0.28    |
| Yes                      | 5 (17.2)              | 0        | 5 (23.8)  |
| No                       | 24 (82.8)             | 8 (100)  | 16 (76.2) |
| **Antiviral therapy, median days (IQR)** |        |           | 0.94    |
|                          | 10.0 (9.0–15.5)       | 11.5 (9.3–14.0) | 10.0 (9.0–17.5) |
| **Glucocorticoids, n (%)** |                       |           | 0.24    |
| Yes                      | 13 (44.8)             | 2 (25)   | 11 (52.4) |
| No                       | 16 (55.2)             | 6 (75)   | 10 (47.6) |
| **Duration, median days (IQR)** |                   |           | 0.49    |
|                          | 5.0 (2.5–6.5)         | 3.5 (3.0–3.5) | 5.0 (2.0–7.0) |
| **Intravascular immunoglobulin therapy, n (%)** |       |           | <0.05   |
| Yes                      | 12 (41.4)             | 0        | 12 (57.1) |
| No                       | 17 (58.6)             | 8 (100)  | 9 (42.9)  |
| **Extracorporeal membrane oxygenation, n (%)** |            |           | 1.00    |
| Yes                      | 2 (6.9)               | 0        | 2 (9.5)   |
| No                       | 27 (93.1)             | 8 (100)  | 19 (90.5) |
| **Combined with traditional Chinese medicine, n (%)** |              |           | 1.00    |
| Yes                      | 26 (89.7)             | 7 (87.5) | 19 (90.5) |
| No                       | 3 (10.3)              | 1 (12.5) | 2 (9.5)   |

COVID-19, coronavirus disease 2019; IQR, interquartile range; N/A, not available.

P-values: Mann–Whitney U-test, chi-square, or Fisher's exact test to compare the moderate and severe group.

Thrombosis in both legs, severe respiratory failure, and heart failure. After sudden cardiac arrests on days 2 and 3 after admission, she was declared dead.

**DISCUSSION**

Henan province and Hubei province are not only border each other, but are also important transportation hubs and economic centers in the country. This geographical proximity and the frequent population exchanges provide an opportunity for the spreading of SARS-CoV-2. This descriptive study investigated the epidemiological and clinical characteristics of the first 29 patients with COVID-19 infection who were admitted to Henan Provincial People’s Hospital, a hospital designated to admit confirmed patients from across Henan. The study revealed valuable information on the characteristics of the first severe COVID-19 infections diagnosed in Henan following the start of the outbreak in Hubei. It also includes outcomes in patients with treatment that included TCMs. Differences in some demographic and clinical characteristics of patients with mild, moderate, and severe disease were significant.

Previous coronavirus outbreaks, SARS-CoV in 2003 and MERS-CoV 2012, challenged the health care system of the country. SARS-CoV resulted in 8,096 infections and 774 deaths, in 29 countries (17). SARS-CoV-2 is highly contagious in humans, with 823,626 infections and 40,598 deaths occurring in more than 200 countries by April 2020. The reported mortality of SARS-CoV has been reported as 5–10% and that of MERS-CoV as 35.7% (18, 19). Only one patient in this series (3.4%) died, which is lower than the 4.3–15% previously reported in Wuhan (20–22). Perhaps the severity of imported COVID-19 infections will be reduced compared with those diagnosed in Hubei province.
TABLE 4 | Symptoms on admission and clinical outcomes of the COVID-19 patients (n = 29).

| Characteristic          | Severity | P-value |
|-------------------------|----------|---------|
|                         | Moderate | Severe  |
| Symptom on admission, n (%) |          |         |
| Fever                   | 26 (89.7) | 7 (87.5) | 19 (90.5) |
| Cough                   | 16 (55.2) | 2 (25)   | 14 (66.7) |
| Sputum production       | 10 (34.5) | 2 (25)   | 8 (38.1)  |
| Shortness of breath     | 8 (27.6)  | 0        | 8 (38.1)  |
| Muscle ache             | 3 (10.3)  | 1 (12.5) | 2 (9.5)   |
| Headache                | 3 (10.3)  | 2 (25)   | 1 (4.8)   |
| Sore throat             | 1 (3.4)   | 1 (12.5) | 0         |
| Fatigue                 | 8 (27.6)  | 4 (50)   | 4 (19.0)  |
| Diarrhea                | 1 (3.4)   | 0        | 1 (4.8)   |
| Nausea and vomiting     | 3 (10.3)  | 0        | 3 (14.3)  |
| Shiver                  | 2 (6.9)   | 1 (12.5) | 1 (4.8)   |
| Clinical outcome, n (%) |          |         |
| Discharged              | 28 (96.6) | 8 (100)  | 20 (95.2) |
| Died                    | 1 (3.4)   | 0        | 1 (4.8)   |

COVID-19, coronavirus disease 2019; N/A, not available.
P-values: Fisher’s exact test to compare the moderate and severe group.

The patients in this series were between 20 and 90 years of age; the largest percentage (9/29; 31%) were middle-aged. Unlike a previous study in Wuhan that reported increased susceptibility in older men, this series included similar percentages of men and women (21). The largest proportion of patients (11/29; 38%) were agricultural workers, the others had diverse occupations. Four patients, two doctors and two nurses, worked in local hospitals and provided care for patients with confirmed COVID-19 infections, which supports the interpersonal transmission of SARS-CoV-2. The median hospital stay was 12 (IQR, 10–16; range, 3–35) days. The only death was of an 86-years-old woman on the third day after admission, and it resulted from respiratory failure for relatively short times to minimize adverse reactions. Some patients received intravenous immunoglobulin therapy because of immune deficiencies.

TCM was found to be effective for treating SARS in 2003 (26). Many ingredients in the mixtures used to treat the COVID-19 infections in this series are routinely used to treat colds, fever, or cough (27). The patients in this series were treated with decoctions, Chinese patent medicines, or both, depending on syndrome differentiation, and had a shorter hospital stay than the other patients. Twenty-three patients were given oxygen therapy on admission in contrast to a previous report that only 1.6% patients needed ICU admission and oxygen therapy (28). Twenty-one patients in this investigation were admitted or transferred to ICU because they required continuous high-flow oxygen therapy, CRRT or ECMO. Antiviral treatment included inhaled interferon alpha (12 million IU/day) for all 29 patients. Oral arbidol (umifenovir) 0.6 g/day, intravenous ribavirin (1.0 g/day), oral lopinavir and ritonavir (800/200 mg/day), or oral chloroquine phosphate (1.0 g/day) were included in the treatment of severely ill patients. Many patients received antibiotic prophylaxis. Glucocorticoids, including methylprednisolone sodium succinate, methylprednisolone, and dexamethasone were given to patients with ARDS or critical respiratory failure for relatively short times to minimize adverse reactions. Some patients received intravenous immunoglobulin therapy because of immune deficiencies.

Study Limitations
The study limitations include the inclusion of cases treated in only one of the three hospitals designated to treat COVID-19 patients in Henan. It is possible that this group of patients does not completely represent the characteristics of infections diagnosed across the province. Also, the inclusion of patients who were transferred from other hospitals may have resulted in bias because of the collection of inaccurate data in the early stages of infection. Secondly, the viral load, which is likely to influence the severity of infection was not included in the analysis. Thirdly, although the patients were stratified by the severity of their clinical and epidemiological characteristics, it was difficult to analyze the association of differences between variables and severity because the load of infection was not determined. Finally, the small sample size makes it difficult to assure an accurate mortality rate or identify potential exposures and risk factors that can trigger the infection. Subsequent studies with larger sample sizes will answer these questions. The study was not an extended investigation of COVID-19 cases in Henan, but its value is in providing early patient and epidemiological data that add to what is known of this emerging viral disease and will be of use in the ongoing effort to control this pandemic.

CONCLUSION
The clinical and epidemiological features of these 29 COVID-19 patients in Henan show that the virus tended to infect middle-aged and older people with underlying diseases. About 21% of the patients were admitted to the ICU, the median hospital stay was 12 days, and the mortality rate was 3.4%. Some differences of the clinical and epidemiological features between patients with moderate and severe disease were significant.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Commission of the Henan Provincial People’s Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

Q-JW and JZ conceived and conceptualized the study. H-YG and Z-YF wrote the initial draft of the article with important feedback from Q-JW and JZ that affected the subsequent revisions. All authors were involved in the editing the article, and agree on the final version.

FUNDING

This study was supported by the National Key R&D Program of China (No. 2017YFC0907401) and the 345 Talent Project of Shengjing Hospital of China Medical University (M0268 to Q-JW).

ACKNOWLEDGMENTS

We would like to thank all the patients involved in our investigation, and the many colleagues who offered their constructive opinions. We also thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript.

REFERENCES

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. (2020) 382:1199–207. doi: 10.1056/NEJMoa200131
2. WHO. Coronavirus Disease 2019 (COVID-19) Situation Report – 72 (2020). Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-2020.pdf
3. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. (2020) 395:689–97. doi: 10.1016/S0140-6736(20)30260-9
4. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. (2020) 92:214–7. doi: 10.1016/j.ijid.2020.01.050
5. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA. (2005) 102:14040–5. doi: 10.1073/pnas.0506735102
6. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. (2019) 17:181–92. doi: 10.1038/s41579-018-0118-9
7. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Milit Med Res. (2020) 7:11. doi: 10.1186/s40779-020-00240-0
8. Lan SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA. (2005) 102:14040–5. doi: 10.1073/pnas.0506735102
9. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. (2020) 92:214–7. doi: 10.1016/j.ijid.2020.01.050
10. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA. (2005) 102:14040–5. doi: 10.1073/pnas.0506735102
11. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. (2019) 17:181–92. doi: 10.1038/s41579-018-0118-9
12. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Milit Med Res. (2020) 7:11. doi: 10.1186/s40779-020-00240-0
13. Province HCoH. A Notice on Releasing “The List of Designated Hospitals for Medical Treatment of Pneumonia Caused by New Coronavirus Infection in Henan Province. (2020). Available online at: http://www.hnwsjsw.gov.cn/contents/177/4(7951).shtml
14. WHO. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. (2020). Available online at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
15. Commission CNH. New Coronavirus Pneumonial Diagnosis and Treatment Program. 5th ed. (2020). Available online at: http://www.nlc.gov.cn/sxc/zhengwjw/202002/3b99b88a4cb9420427b9d5b98912f4440.shtml
16. Ren J, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. (2020) 155:10. doi: 10.1016/j.phrs.2020.104743
17. WHO. Summary of Probable SARS Cases With Onset of Illness From 1 November 2002 to 31 July 2003. (2004). Available online at: https://www.who. int/csr/sars/country/table2004_04_21/en/
18. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respiriolog. (2018) 23:130–7. doi: 10.1111/resp.13196
19. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting Coronaviruses into the spotlight. Viruses. (2019) 11:59. doi: 10.3390/v11010059
20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang I, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. doi: 10.1001/jama.2020.1585
21. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
23. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. (2020) 323:1406–7. doi: 10.1001/jama.2020.2565
24. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. (2020) 63:706–11. doi: 10.1007/s11427-019-81355-7
25. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. (2020) 382:970–1. doi: 10.1056/NEJMoa2001468
26. Zhang MM, Liu XM, He L. Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence. *World J Gastroenterol.* (2004) 10:3500–5. doi: 10.3748/wjg.v10.i23.3500

27. Ni L, Zhou L, Zhou M, Zhao J, Wang DW. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. *Front Med.* (2020) 14:210–4. doi: 10.1007/s11684-020-0757-x

28. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying JJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. *BMJ.* (2020) 368:m606. doi: 10.1136/bmj.m606

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhao, Gao, Feng and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.